OBJECTIVEDiscussing the basic application of scripting in RayStation TPS system.

METHODSOn the RayStation 3.0 Platform, the programming methods and the points should be considered during basic scripting application were explored with the help of utility scripts. The typical planning problems in the field of beam arrangement and plan outputting were used as examples by ironprthon language.

RESULTSThe necessary properties and the functions of patient object for script writing can be extracted from RayStation system. With the help of NET controls, planning functions such as the interactive parameter input, treatment planning control and the extract of the plan have been realized by scripts.

CONCLUSIONWith the help of demo scripts, scripts can be developed in RayStation, as well as the system performance can be upgraded.

Clarithromycin is a 14-membered ring macrolide antibiotics that is widely used in the treatment of infectious disease. Several clinical investigations showed that clarithromycin was highly efficient for multiple myeloma in improving response rate and survival when used in combination with the conventional chemotherapy since 1997. This finding highlights the importance of clarithromycin on the treatment of multiple myeloma. It offers a new regimen for the relapsed/refractory multiple myeloma patients, and provids a new thought for the treatment of multiple myeloma. However, its related mechanism is still unclear, and more investigations are needed. This review summerizes the recent research progress of clarithromycin for treatment of multiple myeloma and its potential mechanisms.
Antineoplastic Combined Chemotherapy Protocols ; Clarithromycin ; Humans ; Multiple Myeloma ; Thalidomide

Histologic transformation (HT) is a frequent event in the clinical course of patients with indolent lymphoma with dismal outcome. The diagnosis of HT is based on clinical manifestation, PET-CT and pathologic biopsy, and the latter is a golden standard for HT. There are contradictory data about the impact of initial management on the risk of transformation. Patients who present with HT did not receive R-CHOP or chemotherapy-naive, should receive this regimen. For the subset of patients received R-CHOP prior to HT, the second line chemotherapy for DLBCL should be adopted. Consolidation with HDT-ASCT should be considered for the suitable young patients. The radio-immunotherapy and novel drugs showed a bright perspective for the patients with HT.
Antineoplastic Combined Chemotherapy Protocols ; Humans ; Lymphoma, Non-Hodgkin

Antineoplastic Combined Chemotherapy Protocols ; Humans ; Multiple Myeloma ; Retrospective Studies

Antineoplastic Combined Chemotherapy Protocols ; Hodgkin Disease ; Humans ; Immunoconjugates ; Immunotherapy

Aged ; Antineoplastic Combined Chemotherapy Protocols ; Humans ; Lymphoma, Mantle-Cell/therapy*

PURPOSE: The purpose of this study was to develop an eye care protocol for intensive care unit (ICU) patients. METHOD: A systematic review was conducted to develop an eye care protocol for ICU patients. Searches were performed using computerized databases (CINAHL, MEDLINE, EBM Review) and citation search from 1996 to January 2007. For the keywords, "eye care", and "randomized controlled trial" were used to identify experimental studies regarding eye care for ICU patients. After reviewing the collected studies, a preliminary eye care protocol algorithm was created. Then, content validity was examined with ophthalmologists and ICU nurses. RESULTS: Six studies were included to serve as a basis for framing of the preliminary algorithm. The final eye care protocol was completed after verifying the preliminary algorithm's content validity. The final eye care protocol was organized in the following manner: 3 items in the assessment stage, 7 items in the no-risk stage, 4 items in the low-risk stage, and 5 items in the high-risk stage. CONCLUSION: The results indicate that, for ICU patients, nurses can broaden their knowledge regarding ocular diseases, as well as improve their practice-based eye care nursing performance.
Antineoplastic Combined Chemotherapy Protocols ; Clinical Protocols ; Cytarabine ; Etoposide ; Eye ; Humans ; Intensive Care Units ; Methotrexate

OBJECTIVETo observe treatment response, survival, safety and the improvement of ECOG in patients with refractory multiple myeloma (MM) with serious heart failure after the administration of continuous low-dose of cyclophosphamide combined with prednisone (CP).

METHODSFrom January 2005 to September 2013, a total of 75 patients were treated by metronomic chemotherapy with continuous low-dose cyclophosphamide (50 mg/d) and prednisone (15 mg/d).

RESULTSAmong the 75 patients, 2 were lost for follow-up. In the 73 available patients, the overall response was 64.4%, including 2 patients (2.7%) with complete remission (CR), 4 cases (5.5%) very good partial remission (VGPR), and 24 patients (32.9%) partial remission (PR). The median survival was 12 months (1-70 months) with a median onset time of 90 days (16-120) and a median progressive freedom survival of 12 months (1-60). The level of B-type natriuretic peptide in responders declined significantly, as compared to no responders [(336.6 ± 30.3) ng/L vs (906.4 ± 104.8) ng/L, P<0.01]. Common adverse events were as follows: 32 (43.8%) cases of bone marrow suppression, 26 (35.6%) cases of infection, 8 cases of dizzy as well as sleepiness (11.0%), 7(9.6%) cases of Cushing syndrome, 4 (5.5%) cases of secondary diabetes mellitus, and 3 (4.1%) cases of edema respectively.

CONCLUSIONThe metronomic chemotherapy of cyclophosphamide combined with prednisone had satisfactory impact on the treatment outcome, including the improvement of cardiac functions and physical capacities, better survival and safety in refractory MM with serious heart failure. It provides a novel regimen for such patients.

A polymer gel dosimeter was fabricated. A 3-dimensional dosimetry experiment was performed in the small field of the photon of the cyberknife. The dosimeter was installed in a head and neck phantom. It was manufactured from the acrylic and it was used in dosimetry. By using the head and neck CT protocol of the CyberKnife system, CT images of the head and neck phantom were obtained and delivered to the treatment planning system. The irradiation to the dosimeter in the treatment planning was performed, and then, the image was obtained by using 3.0T magnetic resonance imaging (MRI) after 24 hours. The dose distribution of the phantom was analyzed by using MATLAB. The results of this measurement were compared to the results of calculation in the treatment planning. In the isodose curve on the axial direction, the dose distribution coincided with the high dose area, 0.76mm difference on 80%, rather than the low dose area, 1.29 mm difference on 40%. In this research, the fact that the polymer gel dosimeter and MRI can be applied for analyzing a small field in a 3 dimensional dosimetry was confirmed. Moreover, the feasibility of using these for the therapeutic radiation quality control was also confirmed.
Antineoplastic Combined Chemotherapy Protocols ; Cytarabine ; Head ; Magnetic Resonance Imaging ; Neck ; Polymers ; Quality Control ; Thioguanine

PURPOSE: To define and measure macular thickness and volume using Fourier domain OCT (FD OCT) and compare the values with Stratus OCT in normal eyes and eyes with macular disease. METHODS: On the same day, macular thicknesses of the ETDRS 9 subfield and total macular volumes were measured in 35 eyes of 23 normal subjects and 19 diseased eyes of 24 patients with FD OCT and Stratus OCT. The macular cube scan protocol for FD OCT and the fast macular thickness map protocol for Stratus OCT were used to measure macular thicknesses. RESULTS: Foveal thickness of the central subfield in FD OCT (251.49+/-79.45 micrometer) was thicker than the value of Stratus OCT (210.26+/-60.57 micrometer) (p<0.001) in all eyes. Total macular volume was 7.72+/-1.06 mm3 and 7.04+/-0.96 mm3 for FD OCT and Stratus OCT, respectively (p<0.001). Retina thickness of the ETDRS 9 subfields in FD OCT was thicker than the value obtained using Stratus OCT. In addition, foveal thickness differences were statistically significant in both the normal and diseased eye groups. CONCLUSIONS: Macular thickness and total macular volume as measured by the FD OCT were larger than the values obtained using the Stratus OCT in both the normal and the diseased eye groups. The measuring algorithm of FD OCT defines the top of RPE as the outer retinal boundary, but Stratus OCT defines the outer retinal boundary as the IS/OS junction of the photoreceptor. Therefore, macular thicknesses of FD OCT are thicker than those of Stratus OCT. This difference should be considered when comparing the results of FD OCT with those of Stratus OCT.
Antineoplastic Combined Chemotherapy Protocols ; Cisplatin ; Doxorubicin ; Eye ; Humans ; Mitomycin ; Retina ; Retinaldehyde ; Tomography, Optical Coherence